InhibOx develops and applies novel and effective computational methods for drug discovery to improve the productivity of lead identification and candidate optimization. The company is also a pioneer in the application of cloud computing to computer-aided molecular design.
Two positions are available at our Oxford offices to work on a collaborative drug discovery project in the area of antibacterial research:
The traditional role of the university has been to teach and conduct original research, but this situation is changing.
Researchers at InhibOx and 
Amazon Web Services (AWS) have just published a case study on InhibOx's use of the cloud under their High Performance Computing section; see 
Professor Graham Richards CBE, Chairman of 
InhibOx develops novel computational methods for drug discovery. Generating high-quality, low-energy conformations of candidate drug molecules is an important aspect in the computational discovery of novel therapeutics. Towards this end, InhibOx's